Clinical Study On Treatment Of Stable Angina Pectoris Of Coronary Heart Disease Combined With Type 2 Diabetes Mellitus(Qi Deficiency And Blood Stasis Syndrome) With Modified Shengxian Decoction

Objective: Clinical efficacy of Observation Shengxian Decoction the treatment of stable angina pectoris of coronary heart disease combined with type 2 diabetes mellitus(qi deficiency and blood stasis syndrome).To provide a viable treatment and provide a rationale for the clinical use of Shengxian Decoctionthe treatment of stable angina pectoris of coronary heart disease combined with type 2 diabetes mellitus(qi deficiency and blood stasis syndrome).Methods: An adaptive randomized controlled approach was used for the study.72 patients who met the inclusion criteria were randomly divided into a test group and a control group,with 36 patients included in each of the two groups.The test group was treated with Shengxian Decoction the basis of Western standard treatment,while the control group was treated with Western standard treatment.The study subjects were assessed for TCM evidence,angina symptoms,monitoring of fasting plasma glucose and Hemoglobin A1 c,electrocardiogram examination,nitroglycerin withdrawal and reduction rate,Seattle Angina Questionnaire and safety index testing.Results: A total of 72 patients meeting the inclusion criteria were included in this trial,no cases were dropped during the trial,no cases were excluded and no cases were discontinued,and a total of 72 cases were finally completed.There were no statistical differences in the general baseline data and various efficacy observation indexes between the two groups before treatment,which were comparable.The results of this trial showed that there was a statistical difference between the total TCM evidence points of the test and control groups after treatment.The Chinese medicine efficacy was calculated by the total TCM syndrome score,and there was a difference in the Chinese medicine efficacy between the two groups,with the test group outperforming the control group.In terms of the efficacy of angina pectoris,the test group showed better improvement than the control group in terms of duration of angina pectoris,frequency of attacks and degree of pain,and the efficacy of angina pectoris was better in the test group than the control group.The fasting plasma glucose and Hemoglobin A1 c of the patients in the trial group were statistically different from those of the control group after treatment.There was no statistical difference in ECG efficacy between the two groups.As assessed by the Seattle Angina Questionnaire after treatment,patients in the trial group were better than the control group in terms of limitation of physical activity,angina stable state,angina attacks and treatment satisfaction,while there was no significant difference between the two groups in terms of disease awareness.There was one case in both the trial and control groups who had not taken nitroglycerin prior to the trial.A comparison of the rate of nitroglycerin withdrawal between the trial and control groups showed a statistically significant difference.Conclusion: Shengxian Decoction combined with Western standardized treatment can effectively relieve the clinical symptoms in patients with stable angina pectoris of coronary heart disease combined with type 2 diabetes mellitus(qi deficiency and blood stasis syndrome),reduce the dosage of nitroglycerin,fasting plasma glucose and Hemoglobin A1 c to improve the prognosis,as well as improve the score of the Seattle Angina Questionnaire and improve the quality of life,the therapeutic effect is obviously better than that of the control group using standardized western medicine alone,and there is no adverse reaction.The clinical trial is safe and effective.